As of 2016, a total of 38 research projects have been undertaken, with the involvement of 38 principal researchers and 266 co-researchers from various Malaysian universities, research institutes and government agencies, in collaboration with industry partners, to help solve some of the issues faced by EBN industry. In the early stage, research areas were focused onfundamental works which are important to provide the scientific basis for some of the claims made by producers, assisting in issues raised by ranchers and industry, and to gather new knowledge in swiftlet and EBN. The researchers worked mainly based on the problems faced by the industry. Besides publications in journals, proceedings and books, more than 30 Masters, PhDs and technical experts have been trained under these projects. In addition, several patents have been filed, social innovations and ideas have been shared with the community and industry. A few products are ready to go to the next level for commercialisation. Industry partners are involved in many of these stepsand outputs. Some of the issues faced by the industry have been partially solved and are in the process of refinement. The engagement with the industry will be further strengthened by getting more industry partners to be involved in the relevantprojects specific to problems faced by the industry, for the benefits of EBN industry and nation’s wealth creation.

In recent times drug repurposing has gained interest over the traditional drug discovery due to reduction in time and cost of development of new drug. Drug repurposing approach has given promising drug candidates for various viral diseases like COVID 19, Ebola, Zika, Dengue, Influenza, HIV, Herpes, etc. Ontarget and off-target are the two basic strategies of drug repurposing. Macrolide, Artemisinin, Quinoline antiparasitic drugs are some of the drugs repurposed against cancer and drugs like thalidomide are repurposed against COVID-19 infection. Repurposing of veterinary drugs like ivermectin, levamisole and benzemidazole group of antiparasitic drugs are also under consideration. This review elaborates repurposing of antihypertensive drugs like angiotensin- converting enzyme inhibitors (ACEI), angiotensin-receptor blockers (ARBs), β-blockers as anti- neoplastic drugs, anti-diabetic drugs against Alzheimer’s disease, fluorophenyl benzimidazole (FPD) as antihypertensive drug, thalidomide against COVID-19 infection, levamisole as antineoplastic drug, benzimidazole as anti-cryptococcal drug and some other new drugs. Usage of in silico techniques and pharmacophore modeling strategies can further accelerate the process of drug repurposing. The drug repurposing strategies significantly minimize research and development costs, provide greater chances of success, shorter research time and lower investment risk.